EA201991661A1 - Соединения и способы трансмембранной доставки молекул - Google Patents
Соединения и способы трансмембранной доставки молекулInfo
- Publication number
- EA201991661A1 EA201991661A1 EA201991661A EA201991661A EA201991661A1 EA 201991661 A1 EA201991661 A1 EA 201991661A1 EA 201991661 A EA201991661 A EA 201991661A EA 201991661 A EA201991661 A EA 201991661A EA 201991661 A1 EA201991661 A1 EA 201991661A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- molecules
- compounds
- methods
- delivery
- transmembrane delivery
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 125000002228 disulfide group Chemical group 0.000 abstract 1
- 230000005684 electric field Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000004526 pharmaceutical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443822P | 2017-01-09 | 2017-01-09 | |
| PCT/IL2018/050031 WO2018127927A1 (en) | 2017-01-09 | 2018-01-09 | Compounds and methods for trans-membrane delivery of molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991661A1 true EA201991661A1 (ru) | 2019-12-30 |
Family
ID=62789169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991661A EA201991661A1 (ru) | 2017-01-09 | 2018-01-09 | Соединения и способы трансмембранной доставки молекул |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11230710B2 (enExample) |
| EP (1) | EP3565603B1 (enExample) |
| JP (1) | JP7348064B2 (enExample) |
| KR (1) | KR20190104392A (enExample) |
| CN (1) | CN110402152B (enExample) |
| AU (1) | AU2018205898B2 (enExample) |
| CA (1) | CA3049640A1 (enExample) |
| EA (1) | EA201991661A1 (enExample) |
| IL (1) | IL267919B2 (enExample) |
| WO (1) | WO2018127927A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11230710B2 (en) | 2017-01-09 | 2022-01-25 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
| US12337036B2 (en) | 2018-01-01 | 2025-06-24 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11318206B2 (en) | 2014-03-28 | 2022-05-03 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
| US10195286B2 (en) * | 2017-07-04 | 2019-02-05 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
| WO2020044349A1 (en) * | 2018-08-30 | 2020-03-05 | Aposense Ltd. | Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules |
| WO2023022055A1 (ja) * | 2021-08-17 | 2023-02-23 | 国立大学法人東海国立大学機構 | 修飾ポリヌクレオチド |
| WO2025096244A1 (en) * | 2023-10-30 | 2025-05-08 | Olfera Corporation | Olfactory delivery scaffolds and methods for making and using same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001507207A (ja) | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 化合物を細胞に送達する方法 |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| AU6974798A (en) | 1997-05-06 | 1998-11-27 | Imarx Pharmaceutical Corp. | Novel prodrugs comprising fluorinated amphiphiles |
| FR2846969A1 (fr) | 2002-11-08 | 2004-05-14 | Salles Jean Pierre | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical |
| SE527131C2 (sv) | 2004-02-13 | 2005-12-27 | Innoventus Project Ab | Steroider för cancerbehandling |
| JP2008505884A (ja) | 2004-07-08 | 2008-02-28 | エヌエスティー・ニューロサバイバル・テクノロジーズ・リミテッド | 疾患を検出する方法および化合物 |
| AU2005281359A1 (en) * | 2004-08-26 | 2006-03-16 | Apparao Satyam | Prodrugs and codrugs containing novel bio-cleavable disulfide linkers |
| EP1804780B1 (en) | 2004-10-01 | 2011-11-16 | ProMetic BioSciences Inc. | Medium-chain length fatty alcohols as stimulators of hematopoiesis |
| PT2360258E (pt) | 2005-02-18 | 2015-01-13 | Angiochem Inc | Moléculas para transportar um composto através da barreira hematoencefálica |
| AU2007299705B2 (en) | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
| EP2620161A1 (en) | 2008-05-13 | 2013-07-31 | University of Washington | Diblock copolymers and polynucleotide complexes thereof for delivery into cells |
| WO2009155335A2 (en) | 2008-06-19 | 2009-12-23 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization |
| CA2753338A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
| US20120035362A1 (en) | 2010-08-03 | 2012-02-09 | Berry And Associates, Inc. | Phosphoramidite derivatives of folic acid |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| MY189533A (en) | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| BR112014030007A2 (pt) | 2012-05-30 | 2017-06-27 | Baylor College Medicine | minivetores superenrolados como uma ferramenta para reparação, alteração e substituição de dna |
| EP2908818A4 (en) * | 2012-10-16 | 2016-07-13 | Endocyte Inc | CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE |
| US20160002159A1 (en) | 2013-02-13 | 2016-01-07 | Neal ZONDLO | Perfluoro-tert-butyl hydroxyproline |
| KR102095085B1 (ko) | 2013-11-18 | 2020-03-31 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온화가능한 양이온성 지질 |
| CA2944141C (en) | 2014-03-28 | 2023-03-28 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
| US9993563B2 (en) | 2014-03-28 | 2018-06-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
| US9889202B2 (en) | 2014-03-28 | 2018-02-13 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
| US20160016855A1 (en) * | 2014-07-21 | 2016-01-21 | Benxin Wu | Fabrication of carbon nanotube-nonoxide structural ceramic nanocomposites through laser sintering |
| EA201991661A1 (ru) | 2017-01-09 | 2019-12-30 | Апосенс Лтд. | Соединения и способы трансмембранной доставки молекул |
| US10195286B2 (en) | 2017-07-04 | 2019-02-05 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
-
2018
- 2018-01-09 EA EA201991661A patent/EA201991661A1/ru unknown
- 2018-01-09 EP EP18736287.6A patent/EP3565603B1/en active Active
- 2018-01-09 KR KR1020197023505A patent/KR20190104392A/ko not_active Withdrawn
- 2018-01-09 CA CA3049640A patent/CA3049640A1/en active Pending
- 2018-01-09 AU AU2018205898A patent/AU2018205898B2/en active Active
- 2018-01-09 US US16/476,557 patent/US11230710B2/en active Active
- 2018-01-09 JP JP2019536976A patent/JP7348064B2/ja active Active
- 2018-01-09 CN CN201880017053.0A patent/CN110402152B/zh active Active
- 2018-01-09 WO PCT/IL2018/050031 patent/WO2018127927A1/en not_active Ceased
- 2018-01-09 IL IL267919A patent/IL267919B2/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11230710B2 (en) | 2017-01-09 | 2022-01-25 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
| US12337036B2 (en) | 2018-01-01 | 2025-06-24 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3565603A4 (en) | 2020-09-09 |
| CA3049640A1 (en) | 2018-07-12 |
| IL267919B1 (en) | 2023-11-01 |
| CN110402152A (zh) | 2019-11-01 |
| KR20190104392A (ko) | 2019-09-09 |
| WO2018127927A1 (en) | 2018-07-12 |
| US11230710B2 (en) | 2022-01-25 |
| US20200392490A1 (en) | 2020-12-17 |
| IL267919A (en) | 2019-09-26 |
| IL267919B2 (en) | 2024-03-01 |
| CN110402152B (zh) | 2024-03-19 |
| AU2018205898B2 (en) | 2020-12-10 |
| EP3565603A1 (en) | 2019-11-13 |
| EP3565603B1 (en) | 2022-12-07 |
| JP7348064B2 (ja) | 2023-09-20 |
| JP2020514299A (ja) | 2020-05-21 |
| AU2018205898A1 (en) | 2019-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991661A1 (ru) | Соединения и способы трансмембранной доставки молекул | |
| MX2018002099A (es) | Compuestos y métodos para la administración transmembranal de moléculas. | |
| Ardura et al. | Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms | |
| Linder et al. | Arsenic trioxide and (−)-gossypol synergistically target glioma stem-like cells via inhibition of hedgehog and notch signaling | |
| MX2016012716A (es) | Compuestos y metodos para suministro trans-membrana de moleculas. | |
| EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
| EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| TR201908994T4 (tr) | Farmasötik bileşimler. | |
| EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
| CY1118826T1 (el) | Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate | |
| EP3023113A4 (en) | TUBELESS LIQUID LIQUID DISPENSING SYSTEM | |
| HK1224291A1 (zh) | 靶向截短的腺瘤性結腸息肉(apc)蛋白的治療法 | |
| MX2019005671A (es) | Sustancias para direccionar diversos organos o tejidos seleccionados. | |
| BR112017012337A2 (pt) | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. | |
| EP4086275A4 (en) | Multimerization delivery system for intracellular delivery of molecule | |
| EP3454868A4 (en) | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS | |
| CY1120892T1 (el) | Σκευασματα δοσολογιας τροποποιητη υποδοχεα οπιοειδων | |
| EP3471829A4 (en) | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp | |
| EA201490862A1 (ru) | Осмотически активная система вагинальной доставки | |
| MX2022009027A (es) | Moleculas autoensamblables para suministro dirigido de farmacos. | |
| EP3801703A4 (en) | Tissue integrated drug delivery system | |
| EP3886911A4 (en) | BIOMEMBRANE COATED NANOPARTICLES (BIONP) FOR THE DELIVERY OF ACTIVE PRINCIPLES TO STEM CELLS |